Nothing Special   »   [go: up one dir, main page]

Toma et al., 2012 - Google Patents

Transforming growth factor-β and atherosclerosis: interwoven atherogenic and atheroprotective aspects

Toma et al., 2012

View HTML
Document ID
7582217886715477089
Author
Toma I
McCaffrey T
Publication year
Publication venue
Cell and tissue research

External Links

Snippet

Age-related progression of cardiovascular disease is by far the largest health problem in the US and involves vascular damage, progressive vascular fibrosis and the accumulation of lipid-rich atherosclerotic lesions. Advanced lesions can restrict flow to key organs and can …
Continue reading at www.ncbi.nlm.nih.gov (HTML) (other versions)

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients

Similar Documents

Publication Publication Date Title
Toma et al. Transforming growth factor-β and atherosclerosis: interwoven atherogenic and atheroprotective aspects
Goumans et al. TGF-β signaling in control of cardiovascular function
Budi et al. TGF‐β as a driver of fibrosis: physiological roles and therapeutic opportunities
Schwartz et al. The intima: soil for atherosclerosis and restenosis
Dookun et al. Therapeutic potential of senolytics in cardiovascular disease
Buhl et al. The role of PDGF-D in healthy and fibrotic kidneys
Suwanabol et al. Transforming growth factor-β increases vascular smooth muscle cell proliferation through the Smad3 and extracellular signal-regulated kinase mitogen-activated protein kinases pathways
Borkham-Kamphorst et al. The PDGF system and its antagonists in liver fibrosis
Tsai et al. TGF-β through Smad3 signaling stimulates vascular smooth muscle cell proliferation and neointimal formation
Lafyatis Transforming growth factor β—at the centre of systemic sclerosis
Gharaee-Kermani et al. Recent advances in molecular targets and treatment of idiopathic pulmonary fibrosis: focus on TGFβ signaling and the myofibroblast
Aschner et al. Transforming growth factor-β: master regulator of the respiratory system in health and disease
Akhurst et al. Targeting the TGFβ signalling pathway in disease
Zalewski et al. Vascular myofibroblasts: lessons from coronary repair and remodeling
Gu et al. Contribution of the anaphylatoxin receptors, C3aR and C5aR, to the pathogenesis of pulmonary fibrosis
Carmeliet et al. Transgenic mouse models in angiogenesis and cardiovascular disease
Pardali et al. TGFβ signaling and cardiovascular diseases
Beyer et al. Stimulation of the soluble guanylate cyclase (sGC) inhibits fibrosis by blocking non-canonical TGFβ signalling
Halwani et al. Role of transforming growth factor–β in airway remodeling in asthma
Rayego-Mateos et al. Interplay between extracellular matrix components and cellular and molecular mechanisms in kidney fibrosis
Fischer et al. Anti-PlGF inhibits growth of VEGF (R)-inhibitor-resistant tumors without affecting healthy vessels
Lupieri et al. Smooth muscle cells-derived CXCL10 prevents endothelial healing through PI3Kγ-dependent T cells response
Ren et al. Novel paracrine functions of smooth muscle cells in supporting endothelial regeneration following arterial injury
Joshi et al. Coagulation‐driven platelet activation reduces cholestatic liver injury and fibrosis in mice
Vandenbriele et al. Platelet endothelial aggregation receptor-1: a novel modifier of neoangiogenesis